Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.
The FDA asked, and Eli Lilly and Company delivered. The company now hopes to secure an additional approval for orforglipron/Foundayo that covers the treatment of type 2 diabetes.
Of all lawsuits filed against patients in 2024 in one U.S. state, physician practices and other non-hospital healthcare entities accounted for 80% of cases. That’s a complete inversion from just six years prior.
In the three or so years since it burst into healthcare, ambient AI scribe technology has run away with the win in the market-uptake race. What has been the return on investment in all those software packages?
Two respected radiology organizations have issued a stark warning on the new recommendations, stating that they risk confusing patients and “may contribute to thousands of additional breast cancer deaths each year.”
Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
